Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
Micron (MU) is having its best trading day since 2011, on track to close at a valuation of $1 trillion, which would make its market cap nearly tied with those of Eli Lilly (LLY) and Berkshire Hathaway (BRK-B, BRK-A). Yahoo Finance Markets and Data Editor Jared Blikre takes a closer look at Micron's market action in the video above.
Eli Lilly agreed to buy three vaccine developers targeting shingles, bacterial infections and Epstein-Barr Virus.
Why Analysts See Eli Lilly as a Long-Term Winner in the Weight-Loss Race
Healthcare stocks were lower Tuesday afternoon, with the NYSE Healthcare Index shedding 0.6% and the
Weight-loss drugs such as Novo Nordisk's Ozempic and Wegovy are disrupting eating habits, and restaurants should prepare for changes, an analyst says. More than half of Americans taking GLP-1 drugs including Eli Lilly's Mounjaro have changed their eating habits, a survey by UBS found. "Our survey results suggest GLP-1 users are more likely to eat less calories while taking GLP-1 drugs, with survey respondents dining out less, changing eating habits, and appreciating healthier foods more," UBS analysts led by Dennis Geiger said in a note to clients.
Walmart (NasdaqGS:WMT) is set to enter the top 10 of the Russell 3000 Index during the June 2026 reconstitution, replacing Eli Lilly. The index change follows Q1 results where Walmart reported record sales alongside a cautious earnings outlook that triggered a sharp stock pullback. Two senior executives are leaving the company as Walmart reshapes its leadership team and refines its long term priorities. For you as an investor, Walmart sits at the crossroads of big box retail, grocery, and e...
Eli Lilly (NYSE:LLY) announced a US$3.8b series of acquisitions in vaccines, including Curevo, LimmaTech Biologics, and Vaccine Company. The company is expanding its presence in infectious disease prevention alongside its established obesity and diabetes drug portfolio. Phase 3 trial results for Eli Lilly’s obesity drug candidate retatrutide showed record weight loss outcomes and strong efficacy signals. These developments introduce fresh data points for investors tracking Eli Lilly’s R&D...
(Bloomberg) -- Eli Lilly & Co. is on a record spending spree, announcing acquisitions worth more than $20 billion so far in 2026 as the drugmaker expands beyond its blockbuster obesity franchise. Most Read from BloombergIran’s Khamenei Says No Going Back for Middle East Rocked by WarUS Strikes Targets in Iran Even as Trump Hails Progress on DealRussia Tells US to Evacuate Its Diplomats and Citizens From KyivThese AI Gurus Are Charging Wall Street Banks $25,000 a DayPutin Signs Law on Use of Army
Positive Phase 1b results support plans for a Phase 2 trial later this year.
The drugmaker is buying three vaccine developers to strengthen its infectious disease pipeline.
Eli Lilly and Co (NYSE:LLY) has announced agreements to acquire three vaccine developers, Curevo, LimmaTech Biologics AG, and Vaccine Company, in transactions valued at up to $3.83 billion combined, as the company expands its research and development efforts into infectious disease...
After a brief cool-off last week, U.S. semiconductor and memory stocks are rallying in Tuesday morning trading, led by Micron, which traded above a $1 trillion market capitalization for the first time.
Novo Nordisk's EU label expansions may widen semaglutide use and boost volumes, but pricing pressure and Lilly rivalry can limit recovery.
Micron stock rose after UBS said the AI boom has changed the memory chip market — and tripled its price target to a Street high.
Micron stock rose after UBS said the AI boom has changed the memory chip market — and tripled its price target to a Street high.
Micron stock rose after UBS said the AI boom has changed the memory chip market — and tripled its price target to a Street high.
Via the deals, Lilly is buying biotechs with lead programmes in preventing shingles, bacteria, and Epstein-Barr Virus.
New Cancer Research Could Be a Massive Game Changer for Ozempic and Mounjaro
Eli Lilly acquired three infectious diseases companies for up to $3.83 billion. Lilly stock ticked higher in response.
Amgen faces LOE headwinds and pricing pressure, yet key growth drugs and biosimilars continue gaining traction.
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Eli Lilly (LLY) will acquire three vaccine developers in all-cash deals with a combined value of up
Polymarket traders are watching one biotech more closely than any other for an acquisition. Viking Therapeutics (NASDAQ: VKTX) carries a 38.5% implied probability of being acquired before 2027, with all-time volume above $1.68 million on that single contract. The hook is obesity. Viking’s VK2735 dual GLP-1/GIP agonist is arguably the most advanced obesity asset not ... If Viking Therapeutics Is Acquired, Here’s Who Wins
Eli Lilly announced deals to acquire three biotechnology companies, Curevo, LimmaTech Biologics, and Vaccine Company for roughly $3.8 billion in total consideration.
Eli Lilly and Company (NYSE:LLY) is one of the best medical stocks to invest in according to billionaires. Eli Lilly and Company (NYSE:LLY) received a rating update from Truist on May 1, with the firm maintaining a Buy rating on the shares with a price target of $1,281. It stated that the company’s retatrutide Phase 3 […]
The deals give Lilly vaccines targeting shingles, bacterial pathogens, and Epstein-Barr virus as it expands beyond weight loss drugs
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
